India's customs department has thrown its weight behind the country's health ministry in a regulatory standoff with billionaire Gautam Adani's airport operations, specifically targeting the sale of nicotine pouches through duty-free retailers. The development marks a significant escalation in the dispute, with a second major government agency now actively opposing what it views as unauthorised marketing of a banned product category. In a formal submission to Mumbai's High Court dated June 22, customs officials directly challenged the Adani Group's core legal defence, asserting that exemptions from import duties and customs taxation do not extend to exemptions from India's broader health and safety regulations.
The confrontation stems from a March inspection conducted by health ministry officials at the Adani Group's Mumbai international airport, where nicotine pouches were discovered being sold in departure area duty-free shops. Health authorities determined the practice violated Indian law, prompting the group to seek judicial intervention at the Mumbai High Court rather than comply with the directive. The Adani Group's strategy has centred on a jurisdictional argument: that retailers operating in international departure zones exist outside the regulatory reach of India's domestic laws, particularly those governing pharmaceutical and health products. This interpretation reflects a broader principle in international aviation, where duty-free zones traditionally operate under distinct regulatory frameworks from domestic commercial spaces.
However, the customs department's legal filing directly dismantles this argument by distinguishing between taxation immunity and regulatory immunity. Officials noted that the concept of goods being "outside customs frontiers" for duty purposes is fundamentally distinct from exemption from health and safety oversight. The department's position suggests that while duty-free shops receive tax advantages unavailable to ordinary retailers, those commercial benefits do not confer immunity from India's substantive laws governing what products may be sold to consumers. This interpretation carries significant implications for the broader duty-free retail ecosystem across Indian airports, potentially establishing that regulatory compliance supersedes the traditional autonomy granted to these retailers.
The Adani Group countered in a July 13 filing that the legal challenge itself was valid because customs authorities issued cease-and-desist instructions without first providing formal warning notices as required by procedure. This procedural defence suggests the company views the regulatory overreach as more problematic than the substance of selling nicotine pouches. Additionally, the group has advanced an argument regarding the intended use of duty-free goods, contending that products sold to departing passengers are legally supplied under an understanding that they will be placed in sealed bags and remain unconsumed until passengers exit India. According to this logic, the group is not facilitating domestic consumption but rather facilitating international passengers' lawful purchases for use abroad.
The customs department swiftly dismissed this interpretation as "untenable," highlighting a practical reality that undermines the group's legal position. Once passengers take physical possession of duty-free goods, nothing prevents them from opening and consuming those products immediately, whether before departure or upon arrival elsewhere. The sealed-bag requirement appears more theoretical than practically enforceable, particularly for rapidly consumable nicotine products designed for immediate use. This factual dispute reveals the tension between traditional duty-free retail assumptions and the modern reality of how passengers actually behave with purchased goods.
Nicotine pouches represent one of the world's fastest-expanding segments within the broader nicotine product market, having gained substantial consumer acceptance in numerous developed nations. These small pouches, placed between the gum and lip, deliver nicotine without combustion or smokeless tobacco's traditional characteristics. Despite their global popularity and rapid market expansion, India has declined to approve these products for commercial sale, maintaining them in a regulatory grey zone that effectively bans their retail distribution. This regulatory stance differs markedly from countries where manufacturers have successfully marketed such products, particularly Philip Morris's Zyn brand, which has achieved remarkable growth in the American market, reportedly doubling sales year-over-year from 2023 to 2024.
The Adani Group's engagement with nicotine pouch imports appears strategically aligned with its ambitious expansion plans across India's airport ecosystem. The company operates eight airports nationally and is pursuing an expansive $11 billion development programme that explicitly incorporates duty-free retail offerings as a revenue component. Since August of the previous year, Adani's operations have imported over $35,000 worth of Zyn and White Fox brands from Swedish Smokeless Solutions, according to Reuters reporting. This investment in inventory suggests confidence in the product category's commercial potential, even as regulatory obstacles mount. The scale of planned airport infrastructure expansion indicates that duty-free retail revenues represent a material consideration in Adani's long-term airport development strategy.
For Malaysian readers, this dispute offers instructive lessons regarding regulatory sovereignty and the balance between commercial interests and public health objectives in aviation retail. Malaysia similarly operates duty-free zones across its international airports and faces comparable questions about the appropriate scope of regulatory oversight for such spaces. The Indian case demonstrates that jurisdictional arguments based on tax classification may prove insufficient to shield retailers from health regulations when products remain genuinely accessible to consumers. Additionally, the involvement of multiple regulatory agencies suggests that single-sector victories by commercial operators may prove temporary if other government bodies pursue overlapping health and safety mandates.
The case also reflects broader Southeast Asian tensions regarding nicotine product regulation. As such products gain global prominence and commercial momentum, individual nations must determine their regulatory posture toward innovations like nicotine pouches, which occupy uncertain territory between tobacco products, pharmaceutical delivery systems, and consumer goods. India's apparent stance of blanket non-approval creates enforcement challenges when such products appear in retail channels, particularly in the complex regulatory environment of airport duty-free operations.
The litigation remains ongoing, with the next hearing scheduled for July 28, ensuring that additional legal arguments and evidence will develop publicly. The outcome carries implications extending beyond the immediate commercial dispute, potentially establishing precedent regarding the enforceability of health regulations within duty-free retail environments across Indian aviation. Should the court rule against Adani, airport retailers throughout India may face similar regulatory exposure regarding prohibited products, regardless of their duty-free status. Conversely, a decision favouring the company could substantially expand the practical immunity available to duty-free operations, creating regulatory arbitrage opportunities that might attract other prohibited or restricted products.
